Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

India is facing a major health crisis, with rising obesity rates across all age groups, leading to increased early mortality ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

Regenerative heart therapy, integrating biocompatible materials with nucleic acids, proteins and live cells, offers a promising personalized approach to treating cardiac ischemic reperfusion injury ...

The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...

The study concluded that treatment with SGLT-2I in conjunction with GLP-1RA may help to reduce the incidence of AF/flutter ...

Dilip Shanghvi is not one for flamboyant statements or headline-grabbing moves. Yet, over the decades, the soft-spoken ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Arrepath Inc. has disclosed UDP-2,3-diacylglucosamine hydrolase (LpxH; bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...